Emerging Indications for a Novel Absorbable Hydrogel Spacer

Posted by Lawrence I. Karsh, MD | Jun 2019

Lawrence I. Karsh, MD, FACS, presented “Emerging Indications for a Novel Absorbable Hydrogel Spacer” during the 29th Annual International Prostate Cancer Update on January 24, 2019 in Beaver Creek, Colorado.

How to cite: Karsh, Lawrence I. “Emerging Indications for a Novel Absorbable Hydrogel Spacer” January 24, 2019. Accessed Apr 2024. https://grandroundsinurology.com/ar-resistance-mechanisms-focusing-on-variants-and-testing/

New Considerations for Oligometastatic Prostate Cancer – Summary:

Lawrence I. Karsh, MD, addresses the problem of long-term complications following prostate radiation therapy and describes how a novel absorbable hydrogel spacer can alleviate these issues. Additionally, he describes how the spacer can improve conventional radiology, enable dose escalation as well as salvage therapy and hypofractionation, and improve the safety of these patients.

About the International Prostate Cancer Update

The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Karsh presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.

About The Author

Lawrence I. Karsh, MD

Lawrence I. Karsh, MD, is a Co-Founder of The Urology Center of Colorado, where he serves as an attending urologist and Director of Research & Co-Chairman of the Advanced Therapeutic Clinic. He is a certified principal investigator, and has been the principal investigator on over 250 clinical trials. He has authored a number of peer-reviewed publications and serves on the editorial boards for Oncology Live, Urologists in Cancer Care, and Bladder Cancer. He is a fellow of the American College of Surgeons, and an active member of the AUA, SUO, ASCO, SWOG, ACS, and the Denver Academy of Surgeons. He has served on the bladder cancer subcommittee and the advisory board for the SUO Clinical Trials Consortium and is a member of the Bladder Cancer Advocacy Network (BCAN) Think Tank. Dr. Karsh completed his general surgery training at the University of Colorado Health Sciences Center (UCHSC) and his urology residency at Brigham and Women’s Hospital/Harvard Medical School. He is an Associate Clinical Professor of Surgery at UCHSC. Dr. Karsh participates in many advisory boards for new drug development. He lectures and teaches at scientific meetings throughout the country.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat